Literature DB >> 12620132

Neuropsychiatric effects of cardiovascular drug therapy.

Seth Keller1, William H Frishman.   

Abstract

Various cardiovascular drugs have been shown to have neuropsychiatric effects that can be harmful or therapeutically beneficial to patients. As an example, both sedation and mental depression have been described in patients receiving centrally acting antihypertensive drugs and beta-adrenergic blockers, related to their antiadrenergic actions. In contrast, because of these antiadrenergic actions, agents like clonidine have been used to treat opiate, alcohol, and nicotine withdrawal, while beta blockers have been used to treat symptoms of performance anxiety, migraine, and psychocardiac disorders. Some antiarrhythmic drugs have been associated with delirium, and digitalis toxicity has been shown to cause hallucinations, mania, euphoria, and depression. The calcium-channel blocker verapamil has been used as an adjunctive treatment in patients with bipolar disorders. Since neuropsychiatric symptoms are seen in patients with cardiovascular disease, clinicians should be aware of the possible relationship between these symptoms and concurrent cardiovascular drug therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12620132     DOI: 10.1097/01.CRD.0000053453.89776.2D

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  23 in total

Review 1.  Imidazoline binding sites on receptors and enzymes: emerging targets for novel antidepressant drugs?

Authors:  Andrew Holt
Journal:  J Psychiatry Neurosci       Date:  2003-11       Impact factor: 6.186

2.  Risk factors for depressive symptoms in glaucoma patients: a nationwide case-control study.

Authors:  Chien-Chia Su; Judy Yi-Chu Chen; Tsing-Hong Wang; Jehn-Yu Huang; Chung-May Yang; I-Jong Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-07       Impact factor: 3.117

3.  Clonidine and auditory hallucinations.

Authors:  Durga Prasad Bestha; Vishal Madaan
Journal:  Innov Clin Neurosci       Date:  2012-09

4.  Anticholinergic medications: an additional contributor to cognitive impairment in the heart failure population?

Authors:  Arslan Shaukat; Amir Habib; Kathleen A Lane; Changyu Shen; Saba Khan; Yaron M Hellman; Malaz Boustani; Adnan S Malik
Journal:  Drugs Aging       Date:  2014-10       Impact factor: 3.923

5.  Effect of Preoperative Beta-Blocker Use on Outcomes Following Cardiac Surgery.

Authors:  Jason B O'Neal; Frederic T Billings; Xulei Liu; Matthew S Shotwell; Yafen Liang; Ashish S Shah; Jesse M Ehrenfeld; Jonathan P Wanderer; Andrew D Shaw
Journal:  Am J Cardiol       Date:  2017-07-24       Impact factor: 2.778

6.  The sensitivity of Na+, K+ ATPase as an indicator of blood diseases.

Authors:  Abulnaja Kkalid Omar; Kherd Ali Ahmed; Nawal Mohammed Helmi; Kumosani Taha Abdullah; Mohamad H Qarii; Huwait Etimad Hasan; Albukhari Ashwag; Alaama Mohammed Nabil; Al-Ghamdi Maryam Abdu; Moselhy Said Salama
Journal:  Afr Health Sci       Date:  2017-03       Impact factor: 0.927

7.  Anxiety and depression symptoms in arterial hypertension: the influence of antihypertensive treatment. the HUNT study, Norway.

Authors:  Aslak Johansen; Jostein Holmen; Robert Stewart; Ottar Bjerkeset
Journal:  Eur J Epidemiol       Date:  2011-12-20       Impact factor: 8.082

8.  Mania-like behavior induced by genetic dysfunction of the neuron-specific Na+,K+-ATPase α3 sodium pump.

Authors:  Greer S Kirshenbaum; Steven J Clapcote; Steven Duffy; Christian R Burgess; Janne Petersen; Karolina J Jarowek; Yeni H Yücel; Miguel A Cortez; O Carter Snead; Bente Vilsen; John H Peever; Martin R Ralph; John C Roder
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-24       Impact factor: 11.205

Review 9.  [Neurological aspects of chronic heart failure].

Authors:  K G Häusler; U Laufs; M Endres
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

Review 10.  Cognitive decline in heart failure.

Authors:  Kannayiram Alagiakrishnan; Darren Mah; Ali Ahmed; Justin Ezekowitz
Journal:  Heart Fail Rev       Date:  2016-11       Impact factor: 4.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.